Neuberger Berman Group
MYGN icon

Neuberger Berman Group’s Myriad Genetics MYGN Stock Holding History

Neuberger Berman Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,174,218
Closed -$24.2M – 1622
2016
Q3 		$24.2M Buy
+1,174,218
New +$29.8M 0.03% 546
2015
Q4 		– Sell
-6,394
Closed -$240K – 1540
2015
Q3 		$240K Sell
6,394
-356
-5% -$12.6K ﹤0.01% 1415
2015
Q2 		$229K Sell
6,750
-1,355
-17% -$46.1K ﹤0.01% 1467
2015
Q1 		$287K Buy
8,105
+220
+3% +$7.87K ﹤0.01% 1440
2014
Q4 		$268K Sell
7,885
-1,030
-12% -$36.5K ﹤0.01% 1478
2014
Q3 		$343K Sell
8,915
-37,820
-81% -$1.41M ﹤0.01% 1428
2014
Q2 		$1.82M Buy
46,735
+36,535
+358% +$1.36M ﹤0.01% 1128
2014
Q1 		$349K Buy
+10,200
New +$316K ﹤0.01% 1404
2013
Q4 		– Sell
-10,430
Closed -$245K – 1645
2013
Q3 		$245K Sell
10,430
-570
-5% -$16.2K ﹤0.01% 1463
2013
Q2 		$296K Buy
+11,000
New +$319K ﹤0.01% 1407

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Neuberger Berman Group's MYGN Position: Q4 2016 in Review

Neuberger Berman Group sold out of Myriad Genetics (MYGN) in Q4 2016, closing a stake of 1,174,218 shares — an estimated $24.2M sold.

Neuberger Berman Group first reported a position in MYGN in Q2 2013 and held it in 10 quarters. The position peaked at $24.2M in Q3 2016. 223 funds tracked by Wall St. Rank hold MYGN as of Q4 2016.

  • Neuberger Berman Group reported no remaining Myriad Genetics position as of Q4 2016 after selling out during the quarter.
  • Neuberger Berman Group sold 1,174,218 Myriad Genetics shares in Q4 2016, an estimated $24.2M.
  • Neuberger Berman Group first reported a position in Myriad Genetics in Q2 2013 and held it in 10 quarters.
  • Neuberger Berman Group's Myriad Genetics position peaked at $24.2M in Q3 2016.
  • 223 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2016.

Based on Neuberger Berman Group's 13F filing for Q4 2016, filed 6 Feb 2017.